Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Bupivacaine hydrochloride + povidone-iodine + lidocaine hydrochloride + triamcinolone** is a compounded multi-component small-molecule drug kit used for local or regional anesthesia and analgesia. The combination includes two amide local anesthetics, bupivacaine hydrochloride and lidocaine hydrochloride, which reduce pain transmission primarily by reversibly blocking voltage-gated sodium channels in peripheral nerves; triamcinolone provides local corticosteroid anti-inflammatory activity via glucocorticoid receptor agonism and downstream suppression of inflammatory gene expression; and povidone-iodine serves as a topical antiseptic through broad microbicidal iodine release. The product has been described under kit names such as MLK F4 KIT, BLT-25 KIT, and P-CARE K40MX/K80MX, including by Asclemed USA, for procedural pain control and related local anesthetic use. It is best characterized as an unapproved compounded combination product rather than an FDA-approved single branded drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupivacaine hydrochloride + povidone-iodine + lidocaine hydrochloride + triamcinolone.